Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 2013; 109(04): 580-581
DOI: 10.1160/TH13-01-0064
DOI: 10.1160/TH13-01-0064
Invited Editorial Focus
Dabigatran elimination: is haemodialysis effective?
Further Information
Publication History
Received:
25 January 2013
Accepted:
25 January 2013
Publication Date:
22 November 2017 (online)
Editorial Focus on ► Khadzhynov et al. Thromb Haemost 2013; 109: 596-605.
-
References
- 1 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
- 2 Ogilvie IM, Newton N, Welner SA. et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 2010; 123: 638-645. e4.
- 3 Wan Y, Heneghan C, Perera R. et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 2008; 01: 84-91.
- 4 Huisman MV, Lip GY, Diener HC. et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012; 107: 838-847.
- 5 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
- 6 Pengo V, Crippa L, Falanga A. et al. Italian Federation of Thrombosis Centers. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost 2011; 106: 868-876.
- 7 Marlu R, Hodaj E, Paris A. et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012; 108: 217-224.
- 8 Woo JS, Kapadia N, Phanco SE. et al. Positive Outcome After Intentional Overdose of Dabigatran. J Med Toxicol. 2012 in press.
- 9 Kamboj J, Kottalgi M, Cirra VR. et al. Direct thrombin inhibitors: a case indicating benefit from ‘plasmapheresis’ in toxicity: a call for establishing “guidelines” in overdose and to find an “antidote”!. Am J Ther 2012; 19: e182-185.
- 10 Stangier J, Rathgen K, Stahle H. et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010; 49: 259-268.
- 11 Chang DN, Dager WE, Chin AI. Removal of Dabigatran by Hemodialysis. Am J Kidney Dis. 2012 in press.
- 12 Wanek MR, Horn ET, Elapavaluru S. et al. Safe use of hemodialysis for dabigatran removal before cardiac surgery. Ann Pharmacother 2012; 46: e21.
- 13 Warkentin TE, Margetts P, Connolly SJ. et al. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 2012; 119: 2172-2174.
- 14 Khadzhynov D, Wagner F, Formella S. et al. Effective elimination of dabigatran by hemodialysis: a phase I single centre study in patients with end stage renal disease. Thromb Haemost 2013; 109: 596-605.
- 15 Blech S, Ebner T, Ludwig-Schwellinger E. et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008; 36: 386-399.